| Literature DB >> 32677025 |
Béla Merkely1, Attila J Szabó2, Annamária Kosztin3, Ervin Berényi4, Andor Sebestyén5, Csaba Lengyel6, Gergő Merkely7,8, Júlia Karády3,9, István Várkonyi10, Csaba Papp4, Attila Miseta11, József Betlehem12, Katalin Burián13, Ildikó Csóka14, Barna Vásárhelyi15, Endre Ludwig16,17, Gyula Prinz16, János Sinkó16,17, Balázs Hankó18, Péter Varga7, Gábor Áron Fülöp3, Kornélia Mag19, Zoltán Vokó20.
Abstract
After months of restrictive containment efforts to fight the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) epidemic, European countries are planning to reopen. To support the process, we conducted a cross-sectional survey among the Hungarian population to estimate the prevalence of infectious cases and prior SARS-CoV-2 exposure. A representative sample (n = 17,787) for the Hungarian population of 14 years or older living in private households (n = 8,283,810) was selected. The study was performed within 16 days after 50 days of restrictions, when the number of confirmed cases was stable low. Naso- and oropharyngeal smears and blood samples were collected for PCR and antibody testing. The testing was accompanied by a questionnaire about symptoms, comorbidities, and contacts. Design-based prevalence estimates were calculated. In total, 10,474 individuals (67.7% taken into account a sample frame error of 2315) of the selected sample participated in the survey. Of the tested individuals, 3 had positive PCR and 69 had positive serological test. Population estimate of the number of SARS-CoV-2 infection and seropositivity were 2421 and 56,439, respectively, thus active infection rate (2.9/10,000) and the prevalence of prior SARS-CoV-2 exposure (68/10,000) was low. Self-reported loss of smell or taste and body aches were significantly more frequent among those with SARS-CoV-2. In this representative, cross-sectional survey of the Hungarian population with a high participation rate, the overall active infection rate was low in sync with the prevalence of prior SARS-CoV-2 exposure. We demonstrated a potential success of containment efforts, supporting an exit strategy. NCT04370067, 30.04.2020.Entities:
Keywords: COVID-19; Cross-sectional; Hungary; Nationwide; SARS-CoV-2
Mesh:
Year: 2020 PMID: 32677025 PMCID: PMC7366154 DOI: 10.1007/s11357-020-00226-9
Source DB: PubMed Journal: Geroscience ISSN: 2509-2723 Impact factor: 7.713
Fig. 1Formulation of the study population. *The sum of the number of positive and negative tests do not add up to the number of the study population (10,474) neither for PCR nor for serology as some persons consented to provide only one type of samples
Characteristics of the study population
| Total study population | Test positive* | Seronegative without positive PCR | Negative PCR test without serology | |
|---|---|---|---|---|
| Men (%) | 4864 (46.4) | 35 (50.0) | 4798 (46.4) | 31 (45.6) |
| Age (years) | ||||
| Mean (SD) | 48.7 (18.0) | 52.2 (18.2) | 48.7 (18.0) | 45.1 (21.3) |
| 14–39 (%) | 3353 (32.0) | 18 (25.7) | 3309 (32.0) | 26 (38.2) |
| 40–64 (%) | 4735 (45.2) | 33 (47.1) | 4676 (45.2) | 26 (38.2) |
| 65– (%) | 2386 (22.8) | 19 (27.1) | 2351 (22.7) | 16 (23.5) |
| BMI (kg/m2)† | ||||
| <18.5 | 322 | 0 | 315 | 7 |
| 18.5–24.9 | 3709 | 21 | 3662 | 26 |
| 25–29.9 | 3589 | 27 | 3546 | 16 |
| 30– | 2774 | 20 | 2736 | 18 |
| Smoking† | ||||
| Never | 5381 | 38 | 5310 | 33 |
| Current | 2933 | 16 | 2904 | 13 |
| Past | 2143 | 15 | 2107 | 21 |
| Any symptoms after 03.01.2020‡ | 4470 | 37 | 4406 | 27 |
| Fever | 239 | 3 | 233 | 3 |
| Fatigue | 883 | 9 | 868 | 6 |
| Body aches | 832 | 12 | 817 | 3 |
| Cough | 1630 | 13 | 1609 | 8 |
| Headache | 2548 | 19 | 2513 | 16 |
| Sore throat | 1290 | 8 | 1276 | 6 |
| Shortness of breath | 432 | 6 | 425 | 1 |
| Abdominal pain | 471 | 4 | 467 | 0 |
| Nausea/vomiting | 333 | 1 | 332 | 0 |
| Diarrhea | 773 | 10 | 758 | 5 |
| Loss of smell or taste | 277 | 12 | 261 | 4 |
| Reported any comorbidities‡ | 4533 | 38 | 4461 | 34 |
| Hypertension | 3549 | 32 | 3489 | 28 |
| Heart disease | 1135 | 11 | 1115 | 9 |
| Diabetes mellitus | 1059 | 7 | 1045 | 7 |
| Chronic pulmonary disease | 522 | 8 | 505 | 9 |
| Chronic renal disease | 262 | 3 | 256 | 3 |
| Chronic liver disease | 141 | 3 | 137 | 1 |
| Current malignancy | 262 | 2 | 256 | 4 |
| Immunodeficiency | 201 | 1 | 200 | 0 |
The relative frequencies of men and age categories in the population are the same as in the sample, as the weights were calibrated to these characteristics. The population estimates of the other relative frequencies are presented in Fig. 2
*Either with positive PCR or positive serological test
†As some of the participants did not answer the question, the percentages do not add up to 100%
‡More than one category could be indicated
Fig. 2Population estimates of the distribution of smoking (a), body mass index (b), symptoms (c), and comorbidities (d) by infection
Population estimates of PCR-positive and seropositive cases
| PCR positive | Seropositive | |||
|---|---|---|---|---|
| Estimated total number | Prevalence per 10,000 (95% CI) | Estimated total number | Prevalence per 10,000 (95% CI) | |
| Total | 2421 | 2.9 (0–6.7) | 56,439 | 68 (50–86) |
| Men | 713 | 1.8 (0–5.8) | 27,323 | 70 (44–95) |
| Women | 1708 | 3.9 (0–10) | 29,115 | 67 (42–92) |
| Age (years) | ||||
| 14–39 | 0 | 0 (0–8.9) | 16,637 | 56 (27–86) |
| 40–64 | 1269 | 3.7 (0–11) | 24,127 | 70 (44–96) |
| 65– | 1152 | 6.1 (0–16) | 15,674 | 83 (39–126) |
| Labor activity | ||||
| Active worker | 1269 | 3.0 (0–9.0) | 22,406 | 53 (33–74) |
| Pensioner | 1152 | 5.4 (0–14) | 23,412 | 109 (66–152) |
| Student, not working | 0 | 0 (0–38) | 4932 | 69 (0–149) |
| Housewife | 0 | 0 (0–142) | 1239 | 73 (0–174) |
| Other non-worker | 0 | 0 (0–27) | 4450 | 43 (1.6–84) |
| Place of work during the epidemic* | ||||
| Commutes several times a week | 1269 | 4.3 (0–13) | 17,329 | 59 (33–84) |
| Commutes once a week | 0 | 0 (0–93) | 948 | 40 (0–130) |
| Home based | 0 | 0 (0–25) | 4128 | 42 (7.7–76) |
| Known contact with a confirmed SARS-CoV-2–infected person or a person being in quarantine | ||||
| Yes | 0 | 0 (0–73) | 3386 | 114 (24–204) |
| No | 2421 | 3.1 (0–7.0) | 52,044 | 66 (48–84) |
| Refused to answer | 0 | 0 (0–252) | 1009 | 106 (0–286) |
| International travel after 03.01.2020 | ||||
| Yes | 0 | 0 (0–79) | 3460 | 106 (12–200) |
| No | 2421 | 3.1 (0–7.0) | 52,979 | 67 (49–86) |
*Only among active workers
Fig. 3Estimated number and PCR positivity and seropositivity by statistical region
Regional distribution of the target and the study population, and estimated PCR-positive and seropositive cases by region
| PCR positive | Seropositive | |||||
|---|---|---|---|---|---|---|
| Region | Total population | Sample size | Estimated total number | Prevalence per 10,000 (95% CI) | Estimated total number | Prevalence per 10,000 (95% CI) |
| Central | ||||||
| Budapest | 1,480,190 | 987 | 1269 | 8.6 (0–26) | 13,393 | 90 (29–152) |
| Pest county | 1,087,523 | 768 | 0 | 0 (0–39) | 6920 | 64 (9.4–118) |
| Transdanubia | ||||||
| Central Transdanubia | 907,796 | 1606 | 439 | 4.8 (0–15) | 6147 | 68 (29–107) |
| Western Transdanubia | 853,686 | 1480 | 0 | 0 (0–20) | 7215 | 85 (40–129) |
| Southern Transdanubia | 747,675 | 1335 | 0 | 0 (0–22) | 3465 | 46 (14–79) |
| Great Plain and Northern Hungary | ||||||
| Northern Hungary | 942,357 | 1458 | 713 | 7.6 (0–24) | 4236 | 45 (4.6–85) |
| Northern Great Plain | 1,212,205 | 1406 | 0 | 0 (0–21) | 8489 | 70 (22–118) |
| Southern Great Plain | 1,052,378 | 1434 | 0 | 0 (0–21) | 6574 | 62 (22–103) |
Characteristics of the confirmed 14 years old and older COVID-19 cases reported until May 16, 2020 in Hungary
| Living in private households | Living in institutions | |
|---|---|---|
| Men | 1080 (41.9) | 360 (40.7) |
| Women | 1500 (58.1) | 524 (59.3) |
| Region | ||
| Central | 1583 (61.4) | 547 (61.9) |
| Transdanubia | 742 (28.8) | 254 (28.7) |
| Great Plain and Northern Hungary | 255 (9.9) | 83 (9.4) |
| Age (years) | ||
| 14–39 | 525 (20.4) | 50 (5.7) |
| 40–64 | 1090 (42.3) | 178 (20.1) |
| 65– | 965 (37.4) | 656 (74.2) |
The numbers in brackets are column percentages